Hypera Pharma is Brazil’s largest pharmaceutical company in net sales. It’s present in all relevant segments of the retail pharmaceutical sector in Brazil, with leadership in several product categories. The company offers high-quality products, and keeps investing in innovation to grow in a sustainable way.
Hypera Pharma is organized into three major business units:
With the umbrella brand Mantecorp Farmasa, the Company operates in several medical specialties in the Primary Care, including the top thirty in the country according to data from Close-Up International, with products such as Predsim, Celestamine, Maxsulid, Diprospan, Mioflex-A and Addera D3; with Mantecorp Skincare it offers dermocosmetics recommended by dermatologists throughout Brazil, also according to Close-Up International. This business unit is supported by a highly-productive team of medical representatives that is responsible for more than 200,000 visits per month.
The Company is a leader in the Brazilian OTC market, according to IQVIA data, with brands such as Apracur, Benegrip, Coristina d, Engov, Epocler and Estomazil, among others. It also operates in the nutritional, sweeteners and vitamin supplement lines, with brands such as Tamarine, Vitasay 50+, Biotônico Fontoura and Zero-Cal.
With the umbrella brand Neo Química, the Company plays an important role in the similar and generics Brazilian markets, being the leader in the similars according to IQVIA data, with brands such as Torsilax, Neosoro, Doralgina, Flavonid and Histamin. The Neo Química brand is promoted directly at the points-of-sale and it is regularly used by more than 80% of Brazilians, according to a research by MillwardBrown.
The strength of the company in the pharmaceutical market is supported by a large-scale and low-cost operation based in the largest pharmaceutical operating complex in Latin America, located in Anápolis, Goiás. It is a 120,000-square meter structure where more than 3,700 employees work. It has the capacity to produce more than 17 billion solid doses, 40 million units of injectable and 330 million units of liquids, creams, oils and lotions.
To support constant innovation in its business, the Company created in 2017 Hynova, the most modern pharmaceutical research center in Brazil, which houses a team of highly qualified professionals, masters and doctors for the development of medicines, dermocosmetics and nutraceuticals, using cutting-edge technology to be a pioneer in Brazil.
The Company also has a broad national sales and distribution structure. Its products are distributed throughout Brazil, directly to retailers, or indirectly through distributors and wholesalers.
Founded in 2001 as Hypermarcas, its corporate name changed in 2017 to Hypera Pharma, evidencing the Company’s new focus in the pharmaceutical market. It is listed in B3’s Novo Mercado since 2008 and currently employs around 7,000 people.
The Company started to operate in December, 2001, and for more than a decade it was one of the leading companies in the consumer goods market in Brazil, participating in the markets of Personal Care, Cleaning and Food until 2006. In 2007, the Company also entered the pharmaceutical market by acquiring DM Indústria Farmacêutica, having subsequently consolidated its position among the leading companies in this sector in Brazil with the acquisitions of Farmasa, in 2008, Neo Química, in 2009 and Mantecorp, in 2011.
In 2012, along with Aché Laboratórios Farmacêuticos S.A., EMS Participações S.A. and União Química Farmacêutica Nacional S.A., the Company formed the joint venture BIONOVIS S.A. – the Brazilian Biotech Phamarceutical Company, which is focused on the biotechnology products segment.
In 2015, the Company began a new cycle in its strategic planning, when it sold its Cosmetics operation to Coty. In 2016, it sold its Condoms operation to Reckitt Benckiser Brazil and in 2017 its Disposables Business to Ontex.
With these divestments, the Company concentrated its operation entirely on the Brazilian pharmaceutical sector and, in 2018, changed its corporate name from Hypermarcas S.A. to Hypera S.A., assuming the corporate brand Hypera Pharma.